Vascular endothelial growth factor A mRNA translation (VEGFA mRNA translation)

Vascular endothelial growth factor A (VEGFA) mRNA translation is the biological process by which the VEGFA protein is synthesized from its messenger RNA template, serving as a critical regulatory node for angiogenesis and vascular permeability. This process is controlled by complex structural elements within the mRNA's 5' and 3' untranslated regions (UTRs), including internal ribosome entry sites (IRES) that allow for protein production even under cellular stress or hypoxia (Weetall et al., 2008). As a therapeutic target, inhibiting VEGFA mRNA translation aims to reduce the levels of all VEGFA isoforms at the source, offering a potentially more robust blockade than agents that target the secreted protein or its receptors (Cao et al., 2009). Small molecules like PTC299 have been developed to selectively interact with these regulatory UTR sequences, thereby inhibiting the assembly of the translation initiation complex and lowering systemic and local VEGFA protein levels (PTC Therapeutics). This approach is primarily investigated for the treatment of solid tumors and neovascular ocular diseases where VEGFA is pathologically overexpressed. However, therapeutic modulation of this target carries safety concerns typical of VEGF inhibition, such as hypertension, proteinuria, and potential interference with normal wound healing (ClinicalTrials.gov).

Other names

VEGF mRNA translationPost-transcriptional regulation of VEGFAVEGFA protein synthesis inhibitionVEGFA IRES-mediated translation

Inhibition of VEGFA protein synthesis by targeting the 5' and 3' untranslated regions (UTRs) of the VEGFA mRNA to prevent ribosome recruitment and translation initiation.